Kati Copley-Merriman, MS, MBA

Vice President, Market Access and Outcomes Strategy

MBA, Marketing
Indiana University, Indianapolis, IN

MS, Organic Chemistry
Purdue University, Indianapolis, IN

BA, Chemistry and German
Smith College, Northampton, MA

Kati Copley-Merriman, MS, MBA, is Vice President of Market Access and Outcomes Strategy at RTI-HS. Ms. Copley-Merriman has more than 35 years of industry experience, including leadership roles in Global Outcomes Research at Eli Lilly, Parke-Davis, and Pfizer. She has experience in all aspects of outcomes research.

In her RTI-HS role, Ms. Copley-Merriman leads a team of outcomes research scientists, medical writers, and reimbursement experts responsible for developing outcomes research strategic plans, literature reviews, disease state summaries, global value dossiers, and reimbursement dossiers. Ms. Copley-Merriman has experience in many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and central nervous system. Ms. Copley-Merriman is an active member of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and was elected to the ISPOR Board for 2010 to 2012. Ms. Copley-Merriman also was appointed to be member of the Value in Health editorial advisory board for November 2014 to November 2022.